Medtronic's drug-coated balloon for dialysis fistulas clears study

Medtronic HQ
The IN.PACT AV balloon is being developed for the U.S., Japan and New Zealand, in different sizes compared to Medtronic’s paclitaxel-coated IN.PACT Admiral device. (Medtronic)

A new version of Medtronic’s drug-coated balloon, designed specifically to help reopen the collapsing fistulas used by patients as access ports for dialysis treatments, has met its primary endpoints in its first large study.  

The medtech giant’s IN.PACT AV balloon is being developed for the U.S. market, as well as Japan and New Zealand, in different sizes compared to Medtronic’s paclitaxel-coated IN.PACT Admiral device.  

The Admiral balloon previously received a CE mark clearing it for use in arteriovenous fistulas in January 2016, and Medtronic currently has no plans to replace that product in the European market, according to a company spokesperson.  

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

IN.PACT AV’s clinical study enrolled 330 patients who had been receiving hemodialysis treatments for an average of 4.3 years. Compared to traditional percutaneous transluminal angioplasty, patients who received treatment with the drug-coated balloon needed 56% fewer reinterventions to maintain their access fistula over 210 days.  

RELATED: Concept Medical racks up breakthrough designations for its drug-coated balloons, now for clearing dialysis fistulas 

According to Medtronic, narrowing fistulas can interrupt critical dialysis treatments, with end-stage renal disease patients having to undergo one to three maintenance procedures each year. 

In the study, the target vessel remained open in 86.1% of treated patients after 180 days, compared to 68.9% in the control group. After 210 days, the IN.PACT arm had a patency rate of 81.4%, versus 68.9% with traditional angioplasty, while safety data were similar. The results were presented at the annual meeting of the Cardiovascular and Interventional Radiology Society of Europe in Barcelona, Spain.

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.